Arcellx stock steadies near $115 after Gilead’s $7.8 billion takeover bid — what traders watch next
Arcellx edged up 0.1% to $113.86 in late-morning trading Tuesday, still trading a touch below the cash offer from Gilead Sciences.
Arcellx stock sticks near $115 after Gilead bid — what could move ACLX next
Arcellx finished Tuesday at $113.75, flat on the day, and then slipped a nickel to $113.70 after the bell—still parked just shy of Gilead’s $115 per share bid. Since the buyout was announced, the stock has surged roughly 77% from its Feb. 20 close.
Arcellx stock jumps 78% on Gilead’s $7.8 billion buyout — deal terms, risks and next catalyst
Arcellx shares were up $49.73, or about 77.6%, at $113.84 in midday New York trade on Monday after Gilead Sciences moved to buy the cancer therapy developer. Gilead slipped 0.6% to $150.42.
Arcellx stock surges toward $115 buyout price after Gilead deal sets new ceiling
Shares of Arcellx surged roughly 78% to $113.92 Monday morning, following news that Gilead Sciences will acquire the cancer therapy maker—pushing the stock close to the buyout price. The takeover puts Arcellx’s valuation as high as $7.8 billion, factoring in a contingent sales-related bonus.
Arcellx (ACLX) Stock Surges on Anito-cel Breakthrough Data as Analysts Boost Price Targets – December 9, 2025
Arcellx, Inc. has jumped back onto Wall Street’s radar after releasing highly positive Phase 2 data for its multiple myeloma cell therapy anitocabtagene autoleucel at the American Society of Hematology 2025 meeting. The new data have driven a sharp move in the stock, a flurry of analyst updates, and renewed debate about valuation ahead of a planned 2026 commercial launch.
TechStock² Updates
![Asia Stock Market Today 29/08/2026 [UPDATE: 00:55 SGT] [PayPal and Nvidia Sink as KASE Global Nears Weekend Close]](https://ts2.tech/wp-content/uploads/2026/08/Asia-market-dashboard-2026-08-29-0053-480x384.jpg "Asia Stock Market Today 29/08/2026 [UPDATE: 00:55 SGT] [PayPal and Nvidia Sink as KASE Global Nears Weekend Close]")
